Mercado Global de Quinolonas – Tendências da Indústria e Previsão para 2030

Análise e dimensão do mercado de quinolonas

A procura de quinolonas está a aumentar 56,8 mil milhões de dólares até 2026. Estima-se também que a crescente procura de quinolonas leve ao crescimento da quota de mercado das quinolonas. O aumento da incidência de doenças infeciosas a nível global atua como um dos principais fatores que potenciam o crescimento do mercado das quinolonas. Estão atualmente disponíveis inúmeras quinolonas para o tratamento de animais em todo o mundo, incluindo aves e peixes.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado das quinolonas no período de previsão 2023-2030. O CAGR esperado do mercado das quinolonas tende a rondar os 4,5% no período de previsão mencionado. O valor de mercado é de 48,8 mil milhões de dólares em 2022 e cresceria para 69,40 mil milhões de dólares até 2030. Para além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário do mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de quinolonas

Market Definition

A quinolone antibiotic is a broad-spectrum bactericide which has a bicyclic core structure having the chemical 4-quinolone. Quinolones are used to treat several bacterial infections in veterinary and human medicine and animal husbandry. They are classified into five distinct classes, in which one is antibiotics. Quinolones are highly effective against stomach, skin, lungs, sinuses, and urinary tract bacterial infections.

Quinolones Market Dynamics

Drivers

• Increased Awareness About Health Issues

Growing health awareness and increasing disposable income have encouraged people to drift towards healthy products, which will benefit them from the adverse health effects. Rising incidence of multidrug-resistant bacteria, raises public health concerns and also creates opportunities for medication producers. Furthermore, the European Medicines Agency's pharmacovigilance risk assessment committee has advised restricting many antibiotics by mouth, inhalation, or injection because of their long-lasting adverse effects. Thus, this expands the market growth.

Opportunities

• Growing Launch of Products

There has been launch of several products that are helpful for the market growth. For instance, in January 2018, Melinta Therapeutics, Inc. launched Baxdela. Baxdela is an oral fluoroquinolone used to treat adult patients with susceptible bacterial acute bacterial skin and skin structure infections (ABSSSI). Baxdela's introduction offers a new therapy alternative and expands the company's infection therapies space. Furthermore, KYORIN Holdings, Inc. announced that the Japanese Ministry of Health, Labor, and Welfare approved Lasvic (lascufloxacin hydrochloride), in September 2019, indicated as a first-line monotherapy for treating community-acquired respiratory and ENT infections. Lasvic's approval is a major milestone in the company's efforts to protect the increasing danger of antimicrobial resistance and provide patients with suitable treatment alternatives.

 Restraints/Challenges

• Adverse Effects of Quinolones

Several side-effects are associated with the use of quinolones, because of which some of the drugs such as Tequin manufactured by Bristol-Myers Squibb have been withdrawn from the market in a very short span after their launch in 2006. As per the United States Food & Drug Administration, Tequin was discontinued because of the adverse reactions in 2.7% of more than 5,000 treated patients. Thus, the adverse effects are restraining the market growth.

This quinolones market market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the quinolones market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Global Quinolones Market Scope

The quinolones market is segmented on the basis of disease type, pathogen type, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Urinary Tract Infection
• Intra-Abdominal Infections
• Blood Stream Infections
• Clostridium Difficile Infections
• Others

Pathogen Type

• Gram-Positive Pathogen
• Gram-Negative Pathogen

Drugs

• Lomefloxacin
• Gatifloxacin
• Norfloxacin
• Moxifloxacin
• Ciprofloxacin
• Others

Route of Administration

• Oral
• Injectable
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Quinolones Market Regional Analysis/Insights

The quinolones market is analyzed and market size insights and trends are provided by disease type, pathogen type, drugs, route of administration, end users and distribution channel as referenced above.

The major countries covered in the quinolones market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing the highest growth for the quinolones market throughout the forecasted period because of the increasing level of disposable income.

North America dominates the market due to the growing number of R&D activities and increasing healthcare expenditure that will boost the market's growth rate in this region.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Cenário competitivo e análise global da quota de mercado das quinolonas

O panorama competitivo do mercado das quinolonas fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados fornecidos acima estão apenas relacionados com o foco das empresas relacionado com o mercado das quinolonas.

Os principais players que trabalham no mercado das quinolonas incluem:

• GSK plc (Reino Unido)
• Novartis AG (Suíça)
• Bayer AG (Alemanha)
• Abbvie, Inc (EUA)
• Merck & Co., Inc.
• Pfizer Inc (EUA)
• (EUA)
• Lupin (Índia)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Grupo Zydus (Índia)
• Bausch Health Companies Inc. (Canadá)
• KYORIN Holdings, Inc (Japão)
• MerLion Pharmaceuticals GmbH (Alemanha)
• WOCKHARDT (Índia)
• Johnson & Johnson Private Limited (EUA)
• Teva Indústrias Farmacêuticas Ltd.(Israel)
• Sanofi (França)

SKU-50361